Your browser doesn't support javascript.
loading
TET2 rs1548483 SNP Associating with Susceptibility to Molecularly Annotated Polycythemia Vera and Primary Myelofibrosis.
Lighezan, Diana L; Bojan, Anca S; Iancu, Mihaela; Pop, Raluca M; Gligor-Popa, Ștefana; Tripon, Florin; Cosma, Adriana S; Tomuleasa, Ciprian; Dima, Delia; Zdrenghea, Mihnea; Fetica, Bogdan; Ionița, Ioana; Gaál, Ildikó O; Vișan, Simona; Mirea, Andreea-Manuela; Popp, Radu A; Florea, Mira; Araniciu, Catalin; Petrescu, Lucian; Pop, Ioan V; Banescu, Claudia; Trifa, Adrian P.
Affiliation
  • Lighezan DL; Department of Hematology, "Victor Babeș" University of Medicine and Pharmacy, 2, Eftimie Murgu Square, 300041 Timișoara, Romania.
  • Bojan AS; Department of Hematology, The Oncology Institute "Ion Chiricuța", "Iuliu Hațieganu" University of Medicine and Pharmacy, 8, Victor Babeș Street, 400012 Cluj-Napoca, Romania.
  • Iancu M; Department of Medical Informatics and Biostatistics, "Iuliu Hațieganu" University of Medicine and Pharmacy, 8, Victor Babeș Street, 400012 Cluj-Napoca, Romania.
  • Pop RM; Department of Pharmacology and Toxicology, "Iuliu Hațieganu" University of Medicine and Pharmacy, 8, Victor Babeș Street, 400012 Cluj-Napoca, Romania.
  • Gligor-Popa Ș; Department of Genetics, The Oncology Institute "Ion Chiricuța", 34-36 Republicii Street, 400015 Cluj-Napoca, Romania.
  • Tripon F; Department of Medical Genetics, "George Emil Palade" University of Medicine, Pharmacy, Science and Technology, 38, Gheorghe Marinescu Street, 540139 Târgu-Mureș, Romania.
  • Cosma AS; Center for Advanced Medical and Pharmaceutical Research, "George Emil Palade" University of Medicine, Pharmacy, Science and Technology, 38, Gheorghe Marinescu Street, 540139 Târgu-Mureș, Romania.
  • Tomuleasa C; Department of Medical Genetics, "George Emil Palade" University of Medicine, Pharmacy, Science and Technology, 38, Gheorghe Marinescu Street, 540139 Târgu-Mureș, Romania.
  • Dima D; Center for Advanced Medical and Pharmaceutical Research, "George Emil Palade" University of Medicine, Pharmacy, Science and Technology, 38, Gheorghe Marinescu Street, 540139 Târgu-Mureș, Romania.
  • Zdrenghea M; Department of Hematology, The Oncology Institute "Ion Chiricuța", "Iuliu Hațieganu" University of Medicine and Pharmacy, 8, Victor Babeș Street, 400012 Cluj-Napoca, Romania.
  • Fetica B; Department of Hematology, The Oncology Institute "Ion Chiricuța", "Iuliu Hațieganu" University of Medicine and Pharmacy, 8, Victor Babeș Street, 400012 Cluj-Napoca, Romania.
  • Ionița I; Department of Hematology, The Oncology Institute "Ion Chiricuța", "Iuliu Hațieganu" University of Medicine and Pharmacy, 8, Victor Babeș Street, 400012 Cluj-Napoca, Romania.
  • Gaál IO; Department of Pathology, The Oncology Institute "Ion Chiricuța", 34-36 Republicii Street, 400015 Cluj-Napoca, Romania.
  • Vișan S; Department of Hematology, "Victor Babeș" University of Medicine and Pharmacy, 2, Eftimie Murgu Square, 300041 Timișoara, Romania.
  • Mirea AM; Department of Medical Genetics, "Iuliu Hațieganu" University of Medicine and Pharmacy, 8, Victor Babeș Street, 400012 Cluj-Napoca, Romania.
  • Popp RA; Department of Genetics, The Oncology Institute "Ion Chiricuța", 34-36 Republicii Street, 400015 Cluj-Napoca, Romania.
  • Florea M; Department of Medical Genetics, "Iuliu Hațieganu" University of Medicine and Pharmacy, 8, Victor Babeș Street, 400012 Cluj-Napoca, Romania.
  • Araniciu C; Department of Medical Genetics, "Iuliu Hațieganu" University of Medicine and Pharmacy, 8, Victor Babeș Street, 400012 Cluj-Napoca, Romania.
  • Petrescu L; Department of Community Medicine, "Iuliu Hațieganu" University of Medicine and Pharmacy, 8, Victor Babeș Street, 400012 Cluj-Napoca, Romania.
  • Pop IV; Department of Therapeutic Chemistry, "Iuliu Hațieganu" University of Medicine and Pharmacy, 8, Victor Babeș Street, 400012 Cluj-Napoca, Romania.
  • Banescu C; Department of Cardiology, "Victor Babeș" University of Medicine and Pharmacy, 2, Eftimie Murgu Square, 300041 Timișoara, Romania.
  • Trifa AP; Department of Medical Genetics, "Iuliu Hațieganu" University of Medicine and Pharmacy, 8, Victor Babeș Street, 400012 Cluj-Napoca, Romania.
J Pers Med ; 10(4)2020 Dec 01.
Article in En | MEDLINE | ID: mdl-33271790
ABSTRACT

BACKGROUND:

The complexity of myeloproliferative neoplasms (MPNs) cannot be characterized by acquired somatic mutations alone. Individual genetic background is thought to contribute to the development of MPNs. The aim of our study was to assess the association between the TET2 rs1548483 single nucleotide polymorphism (SNP) and the susceptibility to polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF) or chronic myeloid leukemia (CML).

METHODS:

We evaluated the TET2 rs1548483 SNP through real-time PCR in 1601 MPN patients out of which 431 with PV, 688 with TE, 233 with PMF, 249 with CML and 197 controls. We included only patients with a molecularly proven driver mutation, such as JAK2 V617F, CALR or BCR-ABL1.

RESULTS:

Significant association between TET2 rs154843 variant allele and JAK2 V617F-positive PV and PMF (OR = 1.70; 95% CI 1.01-2.91; p-value = 0.046, and OR = 2.04; 95% CI 1.10-3.77; p-value = 0.024, respectively), and type 2 CALR-positive PMF (OR = 2.98; 95% CI 1.12-7.93; p-value = 0.035) was noted.

CONCLUSIONS:

The TET2 rs1548483 SNP is associated with the susceptibility to molecularly annotated PV and PMF.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Risk_factors_studies Language: En Journal: J Pers Med Year: 2020 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Risk_factors_studies Language: En Journal: J Pers Med Year: 2020 Document type: Article Affiliation country: